{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:16:11Z","timestamp":1790363771323,"version":"4.1.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV infections in infants, young children, and elderly persons. In May 2023, the FDA approved 2 vaccines, RSVpreF3 (Arexvy\u2122, GSK) and RSVpreF (Abrysvo\u2122, Pfizer), for adults ages 60 years or older to be given as a single-dose intramuscular injection. July 2023 brought the approval of the first long-acting monoclonal antibody nirsevimab (Beyfortus\u2122, Sanofi and AstraZeneca) for the prevention of RSV disease in infants and young children. Then in August, the FDA approved a vaccine (Abrysvo\u2122, Pfizer) to be given to pregnant women to protect their newborns through passive immunity. This article focuses on nirsevemab that has been recommended by the Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics (AAP) to be administered for all infants &lt;8 months of age and for children 8 to 19 months of age who are at increased risk for severe RSV disease.<\/jats:p>","DOI":"10.1089\/ped.2024.0025","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T16:03:47Z","timestamp":1710432227000},"page":"3-6","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":29,"title":["Nirsevimab: A Review"],"prefix":"10.1177","volume":"37","author":[{"given":"Howard","family":"Balbi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Good Samaritan University Hospital, West Islip, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac120"},{"key":"e_1_3_3_3_2","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen WP","year":"1986","unstructured":"Glezen WP, , Taber LH, , Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child, 1986; 140:543\u2013546; doi: 10.1001\/archpedi.1986.02140200053026","journal-title":"Am J Dis Child"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","unstructured":"Cohen C Kleynhans J Moyes J et al. Incidence and Transmission of Respiratory Syncytial Virus in Urban and Rural Communities in South Africa 2017\u20132018: Results of the PHIRST Cohort Study. Available from: https:\/\/ssrn.com\/abstract=4444438 or http:\/\/dx.doi.org\/10.2139\/ssrn.4444438","DOI":"10.2139\/ssrn.4444438"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2112186"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804877"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa752"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac300"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41479-022-00098-x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.179"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7229a4"},{"key":"e_1_3_3_12_2","unstructured":"Food and Drug Administration. Beyfortus (nirsevimab-alip) Product Label. Silver Spring MD: US Department of Health and Human Services Food and Drug Administration; 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf [Last accessed: February23 2024]."},{"key":"e_1_3_3_13_2","unstructured":"Food and Drug Administration: FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Press Release. Silver Spring MD: US Department of Health and Human Services Food and Drug administrations; 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants [Last accessed: February23 2024]."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.32082"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Kimberlin DW Barnett ED Lynfield R et al. American Academy of Pediatrics Committee on Infectious Diseases. Respiratory Syncytial Virus (Section 3). In: Red Book: 2021\u20132024 Report of the Committee on Infectious Diseases. American Academy of Pediatrics: Itasca IL; 2021; pp. 628\u2013636.","DOI":"10.1542\/9781610025225-part03-ch114"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1928"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913556"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214773"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00321-2"},{"key":"e_1_3_3_20_2","unstructured":"CDC. ACIP Evidence to Recommendations for Use of Nirsevimab in Infants Born During RSV Season and Entering Their First RSV Vaccine. U.S. Department of Health and Human Services CDC: Atlanta GA; 2023. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/nirsevimab-season1-rsv-infants-children-etr.html"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060435"},{"key":"e_1_3_3_22_2","unstructured":"CDC ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8\u201319 Months of Age with Increased Risk of Severe Disease Entering Their Second RSV Season. U.S. Department of Health and Human Services CDC: Atlanta GA; 2023. Available from: https:\/\/www.cdc.gov\/vaccines\/acip\/recs\/grade\/nirsemivab-season2-rsv-infants-children-ett.html"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7214a1"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000772"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708939"},{"key":"e_1_3_3_26_2","unstructured":"CDC. General Best Practice Guidelines for Immunization. U.S. Department of Health and Human Services CDC: Atlanta GA; 2023. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html"},{"key":"e_1_3_3_27_2","unstructured":"Sanofi Press Release: Available from: https:\/\/www.news.sanofi.us\/2023-02-01-Sanofi-launches-Beyfortus-R-nirsevimab-alip-Reservation-Program-for-2024-2025-RSV-season-in-U-S"},{"key":"e_1_3_3_28_2","unstructured":"CDC. Health Alert Network (HAN) No .499-Limited Availability of Nirsevimab in the United States\u2014Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) During the 2023\u20132024 Respiratory Virus Season. U.S. Department of Health and Human Services CDC: Atlanta GA; 2023. Available from: https:\/\/emergency.cdc.gov\/han\/2023\/han00499.asp"},{"key":"e_1_3_3_29_2","unstructured":"CDC. Clinician Outreach and Communication Activity (COCA Now)\u2014Updated Guidance for Health Care Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) During the 2023\u20132024 Respiratory Virus Season. Available from: https:\/\/emergency.cdc.gov.\/newsletters\/coca\/2024\/0 [Last accessed: February23 2023]."}],"container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ped.2024.0025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2024.0025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2024.0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:16:08Z","timestamp":1777677368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ped.2024.0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1089\/ped.2024.0025"],"URL":"https:\/\/doi.org\/10.1089\/ped.2024.0025","relation":{},"ISSN":["2151-321X","2151-3228"],"issn-type":[{"value":"2151-321X","type":"print"},{"value":"2151-3228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}